Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $109.2 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.
Shares of the biotechnology company have underperformed the broader market over the past year. VRTX has declined 3.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 25.1%. In 2026, VRTX’s stock fell 5.1%, compared to the SPX’s 8.6% rise on a YTD basis.